A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

Inclusion Criteria :

* Participant must be ≥18 years of age at the time of signing the informed consent.
* Participants who have histological or cytologically confirmed adenocarcinoma of the pancreas.
* Participants with an initial diagnosis of progressive metastatic disease
* Participants with a confirmed diagnosis of metastatic adenocarcinoma of the pancreas with disease progression following gemcitabine-based therapy.
* Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
* Adequate haematological parameters
* Adequate hepatic function
* Adequate renal function
* Adequate coagulation
* No clinically significant abnormalities in urinalysis results
* Electrocardiogram (ECG) without any clinically significant findings
* Participants known to be infected with controlled human immunodeficiency virus (HIV)
* Male and female participants: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
* Capable of giving signed informed consent

Exclusion Criteria :

* Have only localised advanced disease.
* History of any second malignancy in the last 2 years.
* Known history of central nervous system metastases
* Clinically significant gastrointestinal disorder including hepatic disorders, bleeding, inflammation, occlusion, diarrhoea \>Grade 1, malabsorption syndrome, ulcerative colitis, inflammatory bowel disease or partial bowel obstruction.
* Concurrent illnesses that would be a relative contraindication to trial participation such as active cardiac or liver disease
* Active infection or an unexplained fever \>38.5°C on the first scheduled day of dosing
* Neuroendocrine tumour (carcinoid, islet cell) or acinar pancreatic carcinoma
* History of interstitial lung disease, history of slowly progressive dyspnoea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies.
* Exposure to a non-liposomal irinotecan or SN-38 based regimen within 4 weeks prior to randomisation, or exposure to Onivyde or other irinotecan based liposomal products within 6 weeks prior to randomisation
* Major surgery, other than diagnostic surgery, within 4 weeks prior to randomisation
* Participants who have received a live vaccine within 4 weeks prior to randomisation.
* Use of strong CYP3A inhibitors or inducers, or strong inhibitors of UGT1A1.
* Investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to study intervention on Cycle 1 Day 1
* Known low or absent dihydropyrimidine dehydrogenase (DPD) activity.
* Homozygous for the UGT1A1\*28 allele.
* Known hypersensitivity to any of the components of Onivyde injection, other liposomal products, or any components of 5-FU, or LV
* Presence of any contraindications outlined in the Contraindications or Warnings and Precautions sections of the IB for Onivyde, or in the prescribing information for 5-FU or LV.
* Participants who, in the opinion of the investigator, have symptoms or signs suggestive of clinically unacceptable deterioration of the primary disease at the time of screening
* Any other medical or social condition deemed by the investigator to be likely to interfere with a participant's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results